Sanofi India Share Price ₹3,079 | P/E 20.7

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Financials of Sanofi India

Quarter-by-quarter operating performance

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Sales +	736	515	491	469	511	464	524	515	536	406	475	420	472
Expenses +	507	393	377	370	374	348	404	397	364	311	341	330	330
Operating Profit	230	122	114	100	137	116	120	118	172	95	134	90	143
OPM %	31%	24%	23%	21%	27%	25%	23%	23%	32%	23%	28%	22%	30%
Other Income +	44	57	82	77	41	21	2	14	3	9	-22	3	4
Interest	0	1	0	0	0	0	0	0	0	0	0	1	0
Depreciation	10	9	9	9	9	9	9	10	10	9	9	10	9
Profit before tax	264	169	186	167	169	127	113	122	165	94	102	83	138
Tax %	28%	27%	18%	18%	19%	19%	27%	25%	28%	26%	26%	26%	26%
Net Profit +	190	123	152	138	137	103	82	91	120	70	76	62	103
EPS in Rs	82.78	53.43	66.17	59.87	59.39	44.96	35.74	39.70	51.96	30.22	33.04	26.83	44.61

Financials of Sanofi India

Annual income statement trend

	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025	TTM
Sales +	1,977	2,193	2,367	2,460	2,771	3,071	2,902	2,957	2,770	2,851	2,013	1,837	1,774
Expenses +	1,639	1,817	1,832	1,921	2,146	2,403	2,186	2,194	2,066	2,047	1,522	1,346	1,312
Operating Profit	339	376	535	538	625	667	716	762	704	804	491	491	462
OPM %	17%	17%	23%	22%	23%	22%	25%	26%	25%	28%	24%	27%	26%
Other Income +	131	218	66	79	88	33	45	564	204	83	79	-8	-6
Interest	0	0	2	1	1	0	2	2	2	2	2	2	2
Depreciation	97	113	119	102	103	100	82	67	42	40	37	37	37
Profit before tax	373	481	480	515	610	600	677	1,258	864	846	531	445	417
Tax %	29%	33%	37%	37%	38%	31%	29%	25%	28%	29%	22%	27%
Net Profit +	264	322	304	326	381	414	478	944	621	603	414	327	310
EPS in Rs	114.61	139.78	132.26	141.74	165.48	180.09	207.65	410.61	269.83	262.26	179.78	142.04	134.70
Dividend Payout %	39%	46%	51%	50%	51%	194%	176%	119%	211%	64%	65%	87%

Financials of Sanofi India

Capital structure and asset base

	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Equity Capital	23	23	23	23	23	23	23	23	23	23	23	23
Reserves	1,463	1,604	1,860	2,003	2,196	2,419	2,096	2,203	1,253	992	838	726
Borrowings +	0	0	0	0	0	0	23	25	24	19	19	18
Other Liabilities +	742	778	658	751	765	802	777	811	772	681	732	488
Total Liabilities	2,228	2,405	2,541	2,778	2,984	3,244	2,918	3,061	2,072	1,715	1,612	1,255
Fixed Assets +	648	877	817	769	733	499	464	334	306	315	312	304
CWIP	210	22	34	30	21	17	10	13	24	16	18	12
Investments	0	0	0	0	0	0	0	0	0	2	0	0
Other Assets +	1,369	1,505	1,690	1,978	2,230	2,728	2,444	2,714	1,743	1,382	1,281	939
Total Assets	2,228	2,405	2,541	2,778	2,984	3,244	2,918	3,061	2,072	1,715	1,612	1,255

Financials of Sanofi India

Operating, investing and financing cash movement

	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Cash from Operating Activity +	265	213	322	435	374	412	611	559	399	231	462	438
Cash from Investing Activity +	61	36	-155	-79	-73	66	276	631	651	36	-178	-11
Cash from Financing Activity +	-122	-147	-180	-188	-197	-183	-810	-849	-1,583	-878	-392	-448
Net Cash Flow	205	102	-13	168	104	295	78	341	-533	-612	-109	-21
Free Cash Flow	247	184	253	379	317	337	810	574	412	221	426	413
CFO/OP	114%	93%	101%	118%	99%	96%	112%	111%	94%	59%	114%	111%

Financials of Sanofi India

Working capital efficiency and return ratios

	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Debtor Days	21	24	22	29	21	27	19	18	17	17	42	35
Inventory Days	179	173	169	151	154	127	107	110	125	202	186	127
Days Payable	122	81	79	119	110	100	93	105	109	89	151	79
Cash Conversion Cycle	78	115	112	61	65	54	33	22	33	130	77	83
Working Capital Days	26	9	79	17	18	35	-8	-20	-19	24	17	7
ROCE %	22%	26%	27%	26%	29%	28%	32%	35%	41%	71%	49%	58%

IOL Chemicals (Q1 FY27)
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
Innova Captab (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
Glenmark Pharma. (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
Strides Pharma (Q1 FY27)
markets continue to be broad-based growth drivers, with 17% YoY growth and expansion in B2B and B2C markets including Europe, UK, Nordics, Africa, LATAM, MENA…

Sanofi India Q1 FY27 Share Price & Earnings Call Analysis